Pseudomonas Aeruginosa Pneumonia Drug Market
Global Pseudomonas Aeruginosa Pneumonia Drug Market Size, Share & Trends Report by Type (Aerucin, EV-035, MEDI-3902, and Others) and by Application (Hospital, Clinic and Others) Forecast (2022-2028)
The global pseudomonas aeruginosa pneumonia drug Market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). According to the Center for Disease Control(CDC), Pseudomonas aeruginosa refers to a type of bacteria that is found in the environment such as in soil and water. The rise in the prevalence of pneumonia is anticipated to drive the global pseudomonas aeruginosa pneumonia market. For instance, according to the data published by World Health Organization (WHO) in 2021, pneumonia registers for 14% of all deaths in children under 5 years old and killed 740180 children in 2019. The WHO states that pneumonia can be protected with simple interventions, and can be treated with low cost, low tech medication, and care. Thus, Pseudomonas aeruginosa pneumonia drugs are anticipated to play a significant role in the treatment of pneumonia, further driving the growth of the market during the forecast period.
Impact of COVID-19 Pandemic on Global Pseudomonas Aeruginosa Pneumonia Drug Market
The COVID-19 has resulted in a significant impact on the global pseudomonas aeruginosa pneumonia drug market. Pneumonia was considered a serious complication of COVID-19, thus commonly used drug such as Hydroxychloroquine has resulted in a surge in demand for the management of COVID-19. Moreover, the rise in the demand for these drugs has enabled a huge opportunity for the manufacturers of COVID-19 related drugs as it was a global emergency. Thus, the COVID-19 had resulted in a positive impact on the global pseudomonas aeruginosa pneumonia drug market.
Segmental Outlook
The global pseudomonas aeruginosa pneumonia drug market is segmented based on type and application. Based on the type, the market is further sub-segmented into Aerucin, EV-035, MEDI-3902, and others. Based on the application, the market is further sub-segmented into hospitals and clinics. Among these, the hospital segment is anticipated to hold a considerable share in the market owing to a rise in the hospitalization rate due to pneumonia.?
Global Pseudomonas Aeruginosa Pneumonia Drug Market by Type, 2021 (%)
MEDI-3092 is Anticipated to Hold a Prominent Share in the Global Pseudomonas Aeruginosa Pneumonia Drug Market
According to the National Center for Biotechnology Information (NCBI), MEDI 3902 is a bispecific human immunoglobin monoclonal antibody that binds pseudomonas aeruginosa pcrV protein present in host cell cytotoxicity. However, MEDI-3902 is used to prevent nosocomial pneumonia. Moreover, the rising prevalence of nosocomial pneumonia is anticipated to drive the growth of MEDI-3902. For instance, according to data published by NCBI in 2021, nosocomial pneumonia occurs at a rate of 5 to 10 per 1000 admissions and is considered the most common cause of hospital-acquired infection in Europe and the U.S. Thus, the rise in the incidence of nosocomial pneumonia is anticipated to drive the MEDI-3902 segment, further accelerating the growth of global pseudomonas aeruginosa pneumonia drug market over the forecast period.
Regional Outlook
The global pseudomonas aeruginosa pneumonia drug market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among these, the Asia –Pacific region is anticipated to hold a considerable share in the market owing to the rise in government initiatives for pneumonia management.?
Global Pseudomonas Aeruginosa Pneumonia Drug Market, by Region 2022-2028
North America Region is Anticipated to Hold Prominent Share in the Global Pseudomonas Aeruginosa Pneumonia Drug Market
The North American region is anticipated to hold a prominent share in the global pseudomonas aeruginosa pneumonia drug market owing to the rise in the incidence of pneumonia infections. For instance, according to the data published by National Center for Biotechnology Information (NCBI) in July 2021, the annual incidence of pneumonia in the US were 24.8 cases per 10000 adults. However, the rate of incidence is anticipated to rise with the increase in the age of the individual. The mortality rate was 23% for the patients admitted to the intensive care unit (ICU). Thus, the rise in the prevalence of pneumonia is anticipated to drive the growth of the pseudomonas aeruginosa pneumonia drug Market in the region.
Market players Outlook
The major companies serving the global pseudomonas aeruginosa pneumonia drug Market are Aridis Pharmaceuticals LLC, Johnson & Johnson Services Inc., Medlmmune LLC (Astrazeneca), Pfizer Inc., and more among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Phico Therapeutics has received $5.3 million grants from CARB-X for developing an intravenous engineered bacteriophage drug. This drug is used to treat ventilator-associated pneumonia caused by pseudomonas aeruginosa .
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global pseudomonas aeruginosa pneumonia drug market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
- Current Industry Analysis and Growth Potential Outlook
- Impact of COVID-19 on The Global Pseudomonas Aeruginosa Pneumonia Drug Market
- Recovery Scenario of The Global Pseudomonas Aeruginosa Pneumonia Drug Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Aridis Pharmaceuticals Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Boehringer Ingelheim International GmbH
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. Gilead Sciences, Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Medlmmune LLC (Astrazeneca)
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Johnson & Johnson Services, Inc.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Pseudomonas Aeruginosa Pneumonia Drug Market by Type
4.1.1. Aerucin
4.1.2. EV-035
4.1.3. MEDI -3902
4.1.4. Others
4.2. Global Pseudomonas Aeruginosa Pneumonia Drug Market by Application
4.2.1. Hospital
4.2.2. Clinics
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.(Allergan)
6.2. Bayer AG
6.3. Bristol-Myers Squibb Co.
6.4. CARB-X
6.5. Dr. Reddy’s Laboratories Ltd.
6.6. Emergent BioSolutions
6.7. Merck &Co.
6.8. Novartis International AG
6.9. Polyphor Ltd.
6.10. Pfizer Inc.
6.11. Teva Pharmaceuticals Industries Ltd.
1. GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL AERUCIN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL EV-035 IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL MEDI -3902 IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL OTHERS IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
7. GLOBAL HOSPITAL IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL CLINICS IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY TYPE 2021-2028 ($ MILLION)
18. ASIA-PACIFIC GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG , 2021-2028 (%)
4. GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG SHARE BY TYPE, 2021VS 2028 (%)
5. GLOBAL AERUCIN IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG SHARE BY GEOGRAPHY, 2021VS 2028 (%)
6. GLOBAL EV-035 IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SHARE BY GEOGRAPHY, 2021VS 2028 (%)
7. GLOBAL MEDI -3902 IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL OTHERS IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG SHARE BY APPLICATION, 2021VS 2028 (%)
10. GLOBAL HOSPITAL IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG SHARE BY GEOGRAPHY, 2021VS 2028 (%)
11. GLOBAL CLINICS IN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG SHARE BY GEOGRAPHY, 2021VS 2028 (%)
12. US GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
13. CANADA GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
14. UK GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
15. FRANCE GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
16. GERMANY GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
17. ITALY GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
18. SPAIN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
19. REST OF EUROPE GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
20. INDIA GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
21. CHINA GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
22. JAPAN GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
23. SOUTH KOREA GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
24. REST OF ASIA-PACIFIC GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
25. REST OF THE WORLD GLOBAL PSEUDOMONAS AERUGINOSA PNEUMONIA DRUG MARKET SIZE, 2021-2028 ($ MILLION)
